← Back to Search

Diagnostic Imaging

MRI Screening for Prostate Cancer

N/A
Recruiting
Led By Danny J Vesprini, MD, MSc, FRCPC
Research Sponsored by Toronto Sunnybrook Regional Cancer Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be 50 years of age or older
Have positive genetic testing for a pathogenic BRCA1 or BRCA2 mutation
Must not have
Contraindication to receiving low molecular weight MRI contrast agent
Previously diagnosed with prostate cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years january 2016
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether MRI can help detect prostate cancer earlier in men who are at high risk for the disease because they have a BRCA1 or BRCA2 mutation.

Who is the study for?
This trial is for men over 50 who are part of the Male Hereditary Cancer Research Program, have a BRCA1 or BRCA2 mutation, and can undergo an ultrasound biopsy. It's not for those with claustrophobia, MRI contraindications, contrast agent issues, or previous prostate cancer diagnosis.
What is being tested?
The study tests if using MRI as a screening tool helps detect prostate cancer earlier in men at high risk due to BRCA mutations. This is compared to standard PSA testing and digital rectal examination.
What are the potential side effects?
Potential side effects may include discomfort from the MRI procedure or reactions to the contrast agent used during imaging. The biopsy could cause pain, bleeding, infection risks or urinary problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 50 years old or older.
Select...
I have a positive test for a harmful BRCA1 or BRCA2 mutation.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot have MRI contrast due to a medical reason.
Select...
I have been diagnosed with prostate cancer before.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years (january 2016)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years (january 2016) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Prostate MRI in BRCA carriers
Secondary study objectives
Prostate cancer in BRCA carriers

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: MS3TMRI / TRUS Guided BiopsyExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Women's College HospitalOTHER
106 Previous Clinical Trials
43,501 Total Patients Enrolled
Toronto Sunnybrook Regional Cancer CentreLead Sponsor
9 Previous Clinical Trials
893 Total Patients Enrolled
2 Trials studying Prostate Cancer
146 Patients Enrolled for Prostate Cancer
Sunnybrook Health Sciences CentreOTHER
681 Previous Clinical Trials
1,565,698 Total Patients Enrolled
31 Trials studying Prostate Cancer
11,625 Patients Enrolled for Prostate Cancer
Danny J Vesprini, MD, MSc, FRCPCPrincipal InvestigatorSunnybrook Health Sciences Centre

Media Library

MS3TMRI (Diagnostic Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT01990521 — N/A
Prostate Cancer Research Study Groups: MS3TMRI / TRUS Guided Biopsy
Prostate Cancer Clinical Trial 2023: MS3TMRI Highlights & Side Effects. Trial Name: NCT01990521 — N/A
MS3TMRI (Diagnostic Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01990521 — N/A
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top